Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve ...
Rina-S is the last candidate standing from Genmab’s $1.8 billion ProfoundBio acquisition two years ago, with the Danish ...
Just a few days after FDA Commissioner Makary resigned, ally Tracy Beth Høeg is also leaving the agency. Her departure comes ...
CREATE Medicines is working on a clinical-stage pipeline for cancer, while its autoimmune programs are still in preclinical ...
While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted ...
Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...
Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or ...
The FDA's decision last year to make complete response letters public provides new insight into why therapies sometimes fail ...
Renewed pharma interest in GPCR biology and radioligand therapies is drawing attention to functional peptide screening ...
If Biogen has shown that tau can impact cognition, Denali’s technology—validated with an FDA approval in Hunter ...
After a 12-month period that saw the Belgian biotech consider a spinout, swap out CEOs, and enter a three-way acquisition ...
Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company's first quarter earnings call ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results